Prostate Cancer :: Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054

New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73).

Prostate Cancer :: Ontario’s men will be able to have a free PSA test

Ontario’s 2,850,000 men over the age of 40 will be able to have a free PSA test if the Liberals are elected next month. As part of their election health initiative, the Liberals will have OHIP pick up the cost of the test. Currently it costs men in Ontario between $20 and $35 to have the test done.

Prostate Cancer :: University of Minnesota study refutes belief that black men have more aggressive prostate cancer

A University of Minnesota study of prostate cancer tumors from Caucasian and African-American men has shown no evidence that the cancer is more aggressive in black men. Lead investigator Akhouri Sinha, a professor of genetics, cell biology, and development and research scientist at the Minneapolis VA Medical Center, said the belief that black men’s tumors are more aggressive is based on studies that failed to match patients properly and used only indirect means to measure tumor aggressiveness.

Prostate Cancer :: Prostate cancer awareness week, US

Every three minutes a man finds out he has prostate cancer — the second-leading cause of cancer death in American men. In fact, more than 218,890 cases are expected in 2007, making prostate cancer among men more prevalent than breast cancer among women.

Do NOT follow this link or you will be banned from the site!